The financial health and growth prospects of KMPH, demonstrate its potential to underperform the market. It currently has a Growth Score of C. Recent price changes and earnings estimate revisions indicate this would be a good stock for momentum investors with a Momentum Score of A.
Is NLOK a buy or sell?
NortonLifeLock has received a consensus rating of Buy. The company's average rating score is 2.57, and is based on 4 buy ratings, 3 hold ratings, and no sell ratings.
Why is KemPharm dropping?
What happened. Shares of KemPharm (NASDAQ:KMPH) were sinking 12.6% as of 3:33 p.m. EDT on Friday. The big drop came after the drugmaker announced the exercise of existing warrants and the issuance of new warrants.
Is KemPharm a good investment?
KemPharm, Inc. may be overvalued. Its Value Score of D indicates it would be a bad pick for value investors. The financial health and growth prospects of KMPH, demonstrate its potential to underperform the market.
Will KemPharm go up?
On average, Wall Street analysts predict that Kempharm's share price could reach $10.00 by Apr 9, 2022. The average Kempharm stock price prediction forecasts a potential upside of 55.28% from the current KMPH share price of $6.44.
Why is KMPH shorted?
A short squeeze for KemPharm occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of KMPH, which in turn drives the price of the stock up even further.
Who owns KMPH?
Sinclair Broadcast Group
Is KemPharm a buy?
KemPharm has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 1 hold rating, and no sell ratings.